In our new episode, we spoke with Dr. Arnon Heyman, PhD in Plant Biotechnology and CEO of Canonic, a subsidiary of Evogene. Canonic brings new genetics to the cannabis market using a Computational Predictive Biology (CPB) platform which enables them to use Big Data and AI to reach insights within the plant genetics for specific medical indications. Arnon recommends addressing three key industry pains: genetic stability, compound yield and active compounds via the plant genetics. Canonic is a subsidiary of Evogene Ltd. (NASDAQ, TASE: EVGN), the company’s strategy includes the development of Cannabis varieties in order to commercialize medical Cannabis products independently or through collaborations. Canonic has exclusive access to Evogene’s genomic assets and technology for the development of medical Cannabis products. Investors, distributors or growers interested in collaboration are invited to reach Arnon are invited at: arnon.heyman@canonicbio.com Canonic’s website: www.canonicbio.com
Special thanks to Maor Asher, our sound editor.